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In radiosurgery or stereotactic radiotherapy geometric 
inaccuracies are present throughout the treatment chain. 
Besides setup variability and intrafraction motion, geometric 
imperfections in treatment preparation, planning and dose 
delivery become relevant in stereotactic treatment. Their 
impact depends on the type of error (e.g. grand mean, 
systematic, random) and on technological treatment 
characteristics.  
Current perspectives on the management of these geometric 
uncertainties range between two extremes: the radiosurgery 
perspective (single fraction, ablative dose, no margins) and 
the radiotherapy perspective (hypo-fractionated, high dose, 
PTV/PRV margin). Various combinations of and adaptations 
on these perspectives are described in the literature. 
Additional considerations that influence the management of 
geometric uncertainties include: disease site, tumor type, 
treatment intent, treatment risk, radiobiology, clinical 
experience etc. In practice, the ways in which geometric 
uncertainties are accounted for vary per institute, per tumor 
(group) and even per patient; partly because of actual 
differences in geometric treatment characteristics and partly 
as a result of different views.  
Consistent management of geometric uncertainties within 
and across institutes is important for 1. establishing accurate 
dose-effect relations, 2. an unambiguous relationship 
between technology advancement and margin reduction or 
dose prescription for optimal treatment. Therefore, a unified 
perspective on geometric accuracy (with)in radiosurgery and 
stereotactic radiotherapy is warranted. By reviewing and 
comparing the different views, management and nature of 
geometric uncertainties in the chains of radiosurgery and 
stereotactic radiotherapy, we aim to contribute to such a 
unified perspective.  
   
SP-0504   
Impact of geometrical uncertainties in extreme hypo with 
brachytherapy 
N. Nesvacil1, K. Tanderup2, R. Pötter1, C. Kirisits1 
1Medical University of Vienna, Department of Radiation 
Oncology Comprehensive Cancer Center, Vienna, Austria  
2Aarhus University Hospital, Department of Oncology 
Comprehensive Cancer Center, Aarhus, Denmark  
 
This presentation will include an overview of dosimetric 
uncertainties in interstitial/intracavitary brachytherapy and 
summarize the current state of our knowledge on the most 
dominant components for the total dosimetric uncertainties 
for specific types of BT.  
The impact of different systematic and random dosimetric 
uncertainties, caused by geometrical inter- and intra-fraction 
variations between BT applicator and organ positions, on the 
reported total dose (EQD2 for EBRT+HDR brachytherapy) 
depends on the fractionation schedule applied. Examples for 
the effect of reported uncertainties on different high dose 
rate fractionation schedules will include prostate and 
gynaecological BT. 
As the analysis of dose-response relationships depends on the 
reported total treatment doses, large systematic or random 
dosimetric uncertainties for BT will have a significant 
influence on the accuracy of outcome prediction. Based on 
recent literature, e.g. on inter-fraction variations during BT, 
and morbidity studies, the effect of uncertainties on the 
assessment of response probabilities for OARs can be 
estimated.  
Based on this discussion it might be possible to develop 
strategies for reducing uncertainties for dose planning and 
delivery in the future and therefore widen the therapeutic 
window.  
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A massive amount of experimental work in the 1970’s and 
80’s on many models of normal-tissue injury in rodents and 
pigs, showed that “–ln(Surviving Fraction)” is best described 
by a second-order polynomial in dose, the well-known Linear-
Quadratic (LQ) equation. That LQ description has since been 
thoroughly tested in the clinical domain, but almost always in 
the “conventional” range of dose per fraction below 6 Gy. LQ 
is the simplest mathematical description of a non-linear 
relationship and though empirical in nature, it has 
nevertheless been subject to many attempts to connect with 
our understanding of how radiation injury is produced and 
repaired at the cell and molecular level. Yet any meaningful 
and clinically useful link in this respect has remained elusive. 
LQ deals specifically with the relationship between total dose 
and dose per fraction, and with interfraction interval using 
the Incomplete-Repair derivative model. The relationship 
between total dose and overall treatment time is an even 
more complex relationship dependent on the different 
underlying radiobiology of different tissues even within the 
apparently same category of early-reacting or late-reacting 
tissues, distinguished by respectively a “high” or “low” ratio 
of α/β in the LQ equation. Overall time is therefore better 
handled independently of LQ. 
A straightforward but untested hypothesis for the different 
α/β values for early- and late-reacting tissues, is that a 
naturally low α/β for a target cell population is smoothed out 
to a higher value as the sum of the responses of different 
proliferative subpopulations, and different phases of the cell 
cycle that these are in. This explanation could be applied to 
the responses of malignancies in the lung and head and neck, 
also adding in the additional response variation of cells at 
various levels of hypoxia in these sites. Of note is the 
connection between outcome of radiotherapy and HPV status 
in oropharyngeal cancers, which implies a possible difference 
in treatment strategy between these tumor subtypes and 
could also explain the high α/β of head and neck cancer 
overall as the sum of the responses of the different cancer 
subtypes (HPV + and -) which could both have low α/β but 
different radiosensitivity. In some malignancies, notably 
prostate and breast, clinical data do indeed indicate a low 
